ATR and prostate carcinoma: Consistent with these observations, the ATR inhibitor BAY 1895344 cooperated with Olaparib in in vivo models of breast and prostate cancer [60], as did the ATR inhibitor AZD6738 in several ATM-deficient cancers [61].